Treatment With Eribulin Mesylate in Metastatic Breast Cancer

In this segment, panelists explore the cytotoxic agent eribulin mesylate, which has been the focus of several recent clinical trials. In all, despite a growing focus on targeted therapies, cytotoxics remain an important class of drugs in the treatment of patients with metastatic breast cancer.

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

• Categoria